Changes in Hong Kong stocks | Yingpai Pharmaceutical-B (07630) rose more than 10% at the end of the session. Senapali's EU listing application is expected to be approved this month

The Zhitong Finance App learned that Yingpai Pharmaceutical-B (07630) rose more than 10% at the end of the session. As of press release, it rose 6.02% to HK$8.895, with a turnover of HK$687.01 million.

According to the news, Yingpai Pharmaceutical announced that the board of directors decided to use no more than HK$100 million to buy back H shares in the open market. All required capital comes from the company's own funds. Furthermore, depending on market conditions, the company may further repurchase H shares within the scope of the repurchase authorization granted by the shareholders' meeting.

Notably, senapalil received a positive opinion from the European Medicines Agency's Committee on Medicines for Human Use (CHMP) in September. Goldman Sachs said that the statement given by the management of Yingpai Pharmaceuticals on GS Asia Healthcare Enterprise Day is that Senapali's EU listing application is expected to be approved this month, based on receiving positive comments from the CHMP in September.